Exeliom Biosciences
Eugenie Martineau, PhD has a diverse work experience. Eugenie is currently employed as a Senior Operations Manager at Exeliom Biosciences since 2022. Prior to this, they were a Senior Healthcare Consultant and Healthcare Consultant at Alcimed from 2020 to 2022. From 2019 to 2020, they were a Mount Sinai Innovations Partners Fellow at Mount Sinai Innovation Partners. From 2018 to 2019, they were a Postdoctoral Scientist at Icahn School of Medicine at Mount Sinai - Jose Clemente Lab. From 2014 to 2018, they were a PhD Student in Microbiology at Aix-Marseille University - Mignot Lab, where they developed an innovative imaging tool called "Bacto Hubble" and presented at international scientific symposiums. From 2015 to 2014, they were a PhD Student in Microbiology at Princeton University. From 2013 to 2012, they were a Research Assistant at Harvard Medical School - Beckwith Lab. Finally, from 2012 to 2011, they were a Biology Technician at University Hospital, Biochemistry department and an Intern at CHU de Nantes / Medical genetic department - Le Caignec Laboratory.
Eugenie Martineau, PhD obtained their Associate's degree / DUT in Biological and Biochemical analyses from Le Mans Universit\u00e9 in 2009-2011. Eugenie then obtained their Bachelor's degree in Biological/Biosystems Engineering from Polytech Clermont in 2011-2014. Eugenie followed this with a Master's degree in Microbiology: Genome, Ecology and Biotechnology from Universit\u00e9 Blaise Pascal (Clermont-II) - Clermont-Ferrand in 2013-2014. Eugenie then pursued their PhD in Microbiology from Aix-Marseille University in 2014-2017 and a PhD in Microbiology from Princeton University in 2015-2016.
This person is not in any teams
Exeliom Biosciences
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France.